Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LRRC32


Brief Information

Name:Transforming growth factor beta activator LRRC32
Target Synonym:Leucine Rich Repeat Containing 32,D11S833E,Garpin,Leucine-Rich Repeat-Containing Protein 32,LRRC32,Transforming Growth Factor Beta Activator LRRC32,GARP,Glycoprotein A Repetitions Predominant
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
LR2-H5256 Human Human LRRC32 / GARP / Garpin Protein, Fc Tag
ACRO Quality

Part of Bioactivity data


Loaded Human LRRC32, Fc Tag (Cat. No. LR2-H5256) on AHC Biosensor, can bind Human TGFB1, His Tag (Cat. No. TG1-H524x) with an affinity constant of 0.239 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).


Immobilized Human LRRC32, Fc Tag (Cat. No. LR2-H5256) at 2 μg/mL (100 μL/well) can bind Cynomolgus Latent TGF-Beta 1 (C33S), His Tag (Cat. No. TG1-C5243) with a linear range of 0.039-1.25 μg/mL (Routinely tested).

Synonym Name



Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells. LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells. The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
HLX-6018 HLX-6018; HLX6018 Phase 1 Clinical Shanghai Henlius Biopharmaceuticals Co Ltd, Shanghai Henlius Biotech Inc Idiopathic Pulmonary Fibrosis Details
JYB-1907 JYB-1907 Phase 1 Clinical Jiangxi Jemincare Group Co Ltd Solid tumours Details
DS-1055 DS-1055a; DS-1055 Phase 1 Clinical Daiichi Sankyo Co Ltd Solid tumours; Neoplasms; Neoplasm Metastasis Details
HLX-60 HLX-60 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Lymphoma Details
Livmoniplimab MGH-8; ARGX-115; AGRX-115; ABBV151 Phase 1 Clinical Argenx Se Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message